AUSTIN, Texas — Patients on dialysis who are hyporesponsive to anemia treatment will likely experience more red blood cell transfusions, according to data presented at the National Kidney Foundation Spring Clinical Meetings.“Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events and poor outcomes leading to high health care
AUSTIN, Texas —Patients on dialysis who are hyporesponsive to anemia treatment have a higher risk for hospitalizations and death, according to data presented here. “Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events,” Christine Ferro, BA, and colleagues wrote in a poster presented at the National Kidney Foundation Spring Clinical